ABOUT CLVS（仅供参考）

3 Stocks Wall Street Hates

Motley Fool contributors discuss three companies that Wall Street is sour on, why, and whether they agree.

--------------------------------------------------------------------

Many of the healthcare stocks that analysts dislike are high-risk, clinical-stage biotechnology companies, and while I agree that this industry isn't suitable for every investor, I do believe that some of the stocks that analysts rank poorly, including Clovis Oncology (NASDAQ:CLVS), may not be as bad of a bet as these researchers think.

Clovis Oncology has two late-stage cancer drugs under development, including rociletinib, a treatment for non-small cell lung cancer that is under review by the FDA for approval. An FDA decision is expected by March 2016. If rociletinib is approved, I think it could become a billion dollar blockbuster because there's a significant need for new treatment options in patients that have developed resistance to front-line therapy.

Clovis is also close to filing for approval of its ovarian cancer drug, rucaparib, a PARP inhibitor that appears to be especially effective in patients with BRCA gene mutations. In phase 2 trials, 65% of patients responded to rucaparib, suggesting that it could be a much needed alternative for the 22,000 Americans diagnosed annually with this form of cancer. If late stage trial results confirm previous findings, then Clovis Oncology could file for approval by the middle of next year and that may mean Clovis Oncology has two oncology drugs on the market by 2017. Given that potential, I believe Clovis Oncology could be worth the risk.

---------------------------------------------------------------------

 

所有跟帖： 

• Agree. -wsgc- ♀ (166 bytes) () 11/17/2015 postreply 07:12:58

• 谢谢分享！ -Tiger666- ♂ (0 bytes) () 11/17/2015 postreply 07:15:03